Inhaled drug combo aims to ease Heart-Lung bypass weaning
NCT ID NCT05450328
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving two inhaled drugs (milrinone and epoprostenol) before heart-lung bypass can prevent difficult separation from the machine. About 141 adults having heart surgery will be randomly assigned to receive the drug combo or a placebo. The goal is to see if the treatment reduces the need for extra heart support after bypass.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inhaled milrinone and epoprostenol
What this could lead to
If successful, this could provide a safer way to manage pulmonary hypertension and right heart failure during heart surgery, reducing complications.
What could go wrong
This is a phase 2 trial with only 141 participants, so results are preliminary. The drugs are not yet approved by Health Canada for this use, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIGHT VENTRICULAR DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montreal Heart Institute
RECRUITINGMontreal, Quebec, H1T 1C8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••